Pioglitazone has been reported to inhibit ACSL4 to protect breast cancer cells from ferroptosis [36], in parallel, pioglitazone functions as a stabilizer of CISD1 to inhibit mitochondrial iron uptake [18, 22], which dictates another mechanism of pioglitazone in the regulation of ferroptosis. Here, ACSL4 is linked to breast cancer.